New hope for advanced tumors? early trial of IBI3026 begins

NCT ID NCT07327632

Recruiting now Disease control Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called IBI3026 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and check for side effects. About 300 participants will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Sichuan Cancer Hospital
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.